Results 41 to 50 of about 24,787 (310)

Feasibility of continued treatment with dupilumab in patients with type 2 inflammatory disease who developed eosinophilic pneumonia: 3 case reports

Respirology Case Reports
Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP).
Masamitsu Hamakawa, Ayaka Tanaka, Fumiaki Tokioka, Tadashi Ishida   +3 more
doaj   +1 more source

Appropriate Medical Therapy Primarily Modifies Type 2 and Severity Biomarkers in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral ...
Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan   +9 more
wiley   +1 more source

Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators

World Allergy Organization Journal
Objective: Allergen immunotherapy (AIT) and dupilumab have been confirmed to improve symptoms of atopic dermatitis (AD); however, the precise immune mechanisms underlying their efficacy and whether they can elicit synergistic immune effects remain not ...
Jin Liu, MM, Lin Yang, MD, PhD, Qingxiu Xu, MD, Qing Jiang, PhD, Nan Huang, MD, Wenjing Li, PhD, Yaqi Yang, MD, Dongxia Ma, MD, Le Li, MM, Yangxue Fu, PhD, Hao Chen, PhD, Rongfei Zhu, MD, PhD   +11 more
doaj   +1 more source

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]

, 2019
Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos, Navarro-Artieda, Ruth, Sicras-Mainar, Antoni   +2 more
core   +2 more sources

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman, Spencer Short, Emma Tam, Benjamin F. Bitner, Abdulghafoor Alani, Marc Rosen, Mindy Rabinowitz, Damaris Pena Evertz, Elina Toskala, Gurston G. Nyquist   +9 more
wiley   +1 more source

Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims

Dermatology and Therapy
Introduction In clinical trials of patients with atopic dermatitis (AD), conjunctivitis and keratitis occurred more frequently with dupilumab than placebo.
Jessica M. Franklin, Andrea F. Marcus, Ihtisham Sultan, Ashley Howell, Sarah-Jo Sinnott, Jeannette Green, Stephen Ezzy, Robert Gately, Rachel E. Sobel, Florence T. Wang   +9 more
doaj   +1 more source

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma

ERJ Open Research, 2023
Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 
Jonathan Corren, Constance H. Katelaris, Mario Castro, Jorge F. Maspero, Marc Humbert, David M.G. Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe   +12 more
doaj   +1 more source

Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion, Dioni‐Pinelopi Petsiou, Florian C. Fally, Karina Berbalk, Noah F. Melamed, Aldine Tu, Christina Morgenstern, Fana Alem Kidane, Mohammed Zghaebi, Linda Liu, Minghao Pan, Tina J. Bartosik, Victoria Stanek, Katarina Gangl, Julia Eckl‐Dorna, Sven Schneider   +15 more
wiley   +1 more source

Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis

Allergology International, 2023
Background: Eosinophilic otitis media (EOM) is a refractory condition associated with eosinophilic chronic rhinosinusitis and bronchial asthma. EOM is characterized by type-2 inflammation and is refractory to various treatments.
Daiki Nakashima, Tsuguhisa Nakayama, Syunsuke Minagawa, Tetsuya Adachi, Chieko Mitsuyama, Yoko Shida, Tsuneya Nakajima, Shin-ichi Haruna, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources